ViCentra, the Utrecht, Netherlands-based firm behind Kaleido, a small and lightweight wearable insulin pump (“patch pump”), closed a EUR 65m (USD 74m) Collection C financing.
The spherical was led by new investor Companions in Fairness BV, the Amsterdam primarily based Enterprise Capital agency with a long-term focus, with participation from present traders LSP, INKEF Capital and Well being Improvements.
The corporate intends to make use of the funds to increase operations and additional speed up its business rollout, scale its manufacturing operations and put together for FDA submitting. The business launch of the Kaleido system will concentrate on the Netherlands, France, Germany and the UK, with further areas focused in the end.
Led by Frans Cromme, CEO, ViCentra develops, manufactures and markets subsequent era insulin pumps and different merchandise to deal with individuals with diabetes. The corporate’s flagship product is the Kaleido insulin pump which is CE marked and commercially launched in sure European international locations.
As well as, the corporate broadcasts it has commercially launched the subsequent era of its Kaleido system which inserts the DBLG1 System, Diabeloop’s superior closed loop automated insulin supply (“AID”) resolution. By additional strengthening its collaboration with Diabeloop, Kaleido will probably be obtainable to function with the DBLG1 handset and proprietary algorithm. This can convey the primary AID system with a wearable pump to Europe, combining the world’s smallest pump with the superior dosing algorithm and intuitive person interface developed by Diabeloop